October 2025 Updates - The Bioentrepreneurs: Stanford, UCSF, Berkeley

Recent ph1 trial results highlighted in The Lancet editorial

Just completed the One Mind Accelerator - learn more about Xylo's science from this video created as part of the program.

This quarter Xylo can be found at AusBiotech International Conference 2025 and Biological Psychiatry Australia

Emerged from stealth with $25M in funding

Awarded 2nd Place and the People's Choice Award in the WT Innovation World Cup for their wearable blood pressure monitors

On the road! Portal will be attending several events in the near future. To set up a meeting, you can reach out to [email protected]. Find Portal at:

Financing milestone - successfully closed the first tranche of their Pre-A round and are now gearing up for a second close, strengthening their position to advance therapeutic discovery and validation programs

Strategic Partnerships - signed their first paid partnership for therapeutic target discovery in a new cancer indication, marking a major step in translating their Circulome Atlas into actionable insights for drug development

Key Team Additions - expanded their leadership and scientific team with world-class talent from pharma and biotech:

The Data Engine: From Collection to Prediction. Their proprietary dataset continues to expand at Parallel Health, and they're now starting to see what they've been building toward—genuine predictive capabilities. Their models are beginning to predict skin flares, sensitivity patterns, antibiotic resistance, and aging markers. They're also going to be exploring early indicators for skin cancer detection, though they're approaching this carefully and scientifically as they gather more data.

Derm Dream Team. To accelerate their work and ensure clinical rigor, they're finalizing their "Derm Dream Team"—a select cohort of dermatologist KOLs who are both investors and advisors to Parallel. These leading dermatologists span specialties from inflammatory disease to oncology to aging, and represent practices across the United States. They will be instrumental in guiding their proprietary AI predictive health models. They'll be announcing names once finalized, and they're thrilled to welcome this caliber of clinical expertise to their mission

Investor Interest: If you are an investor with clinical/healthcare/wellness expertise and looking for your next investment, they'd welcome a conversation. BTW - as of last month, they're now profitable. Find a time here.

Rolled out their first subscription plans: Free and Starter

Free plan: All existing accounts have been moved here automatically - no need to re-register. It includes limited access to core Copilot and Explorer features.

Starter Plan: enhanced access to Nextnet Copilot and Explorer

See the pricing of these new offerings here

Will be attending CALISCC Suppliers' Day on October 29-30! Their team will be sharing insights on Absotride™, their proprietary peptide-based skin penetration technology platform, which enhances the penetration and bioavailability of active ingredients in skin tissue. Absotride™ unlocks new possibilities in dermatology therapeutics, hair & scalp care, and advanced skincare applications. Their team looks forward to connecting with raw material suppliers, brands, and industry partners during the event. If you are attending the event and would like to learn more or meet with them, please reach out to Lynzee Havert ([email protected]) to arrange a time.

Officially kicked off prototype development — an important step toward bringing Kascaid’s tech into the hands of clinicians and trial partners

Will be at ACR Convergence 2025 in Chicago (Oct 24–29)! If you’ll be there, go find them — they’d love to share what they’re building and connect in person.

Selected to the Creative Destruction Lab Advanced Therapies Program cohort for 2025-26. This prestigious global accelerator program, which has helped generate $51B in equity value for participating companies, is deeply committed to the goal of enhancing the commercialization of science for the betterment of humankind. Inapill’s mission to develop 1st-in-class small molecule therapeutics targeting immunometabolism to address significant unmet patient need across age-related chronic inflammatory & autoimmune diseases is strongly aligned with this goal.

Fundraising: actively raising a $3M Seed round, and has received a soft commitment for up to $1.5M to lead the round from a VC actively investing in the SF Bay Area biotech ecosystem. Inapill is currently working together with this VC to identify a co-lead investor. If interested in participating in the round, please contact Inapill CEO & co-founder Greg Timblin to learn more ([email protected]).

Just launched a new program! STEM EdTech 

Will be speaking at many events in the next month! Listen to them speak at: 

Won 2 pitch competitions in the past month, including one with a $25k prize, and will be pitching twice during SF Tech Week on their AI + high-throughput screening platform for antibody discovery

CEO and founder Luke Blauch is co-hosting San Francisco’s first VC Village on 10/21, an investor-only meet up with free food, drinks, and no pitches. Dozens have already signed up and space is filling fast. Investors can RSVP here

Launched new features for DiffuseSandbox, a no-code web app to design binders for protein targets that leverages Diffuse's latest AI model. 

Team-building: Cache found their Head of Chemistry! This individual (to be announced later this fall) is currently the Chief Scientific Officer of a growing molecular diagnostics company and will support their team as they pursue new biomaterial horizons. Thank you to The Bioentrepreneurs Newsletter for helping us get the word out!

Technical validation: Their second aims in studies with both Stanford University and Princess Margaret Cancer Centre proved to be successful in preserving delicate clinical biomarker signatures in short- and long-read sequencing settings (they are preparing manuscripts for both studies).

Fundraising: The Cache team has been on the road pitching! CEO Michael Becich was awarded the East Bay SBDC Award at the Startup World Cup Regional. Cache also presented at the MedInvest Conference in Palo Alto (check out our recording if you weren't able to be there in-person). Holler if you'll be at SF Tech Week or ASHG 2025 in Boston next week! Reach out to [email protected] if you are interested in participating in Cache's current round

Investment Update: Tensor Ventures, a deep tech investor backed by the European Investment Fund, joined Aperture as their latest investor

Hiring: Aperture is growing their team and currently have three open drug development positions (more info):

Fundraising: Aperture is raising their Seed round to advance new drugs to clinic. If you’re interested in learning more, contact [email protected]

Meet the Team! The team will be attending multiple events in October, including: